Get started
Work

400TiP: PYNNACLE phase II assessing rezatapopt in patients with advanced solid tumors, including lung cancer, harboring a TP53 Y220C mutation

Year: 2025
Type: article
DOI: 10.1016/s1556-0864(25)00592-1
Authors: M.J. De Miguel, E.E. Dumbrava, A. Body, L. Eberst, J-S. Frenel, A. Italiano, M.L. Johnson, J. Kaczmar, S. Kummar, P.M. Lorusso, M. Millward, I.L. Ray-Coquard, G. Scambia, A. Spira, D.S. Tan, J.A. Thompson, Y. Qin, M. Fellous, A. Schram
Institutions: Hospital Universitario HM Sanchinarro, The University of Texas MD Anderson Cancer Center, Monash Health, Monash University, Institut de Cancérologie Strasbourg, Institut de Cancérologie de l'Ouest, Université de Bordeaux, Institut Bergonié, Sarah Cannon, Medical University of South Carolina, Oregon Health & Science University, OHSU Knight Cancer Institute, Yale Cancer Center, Linear Clinical Research, Centre Léon Bérard, Agostino Gemelli University Polyclinic, Virginia Cancer Specialists, National University of Singapore, National University Cancer Institute, Singapore, National University Hospital, Fred Hutch Cancer Center, PMV Pharmaceuticals, Inc. (United States), Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Gilead Sciences, American Society of Clinical Oncology, Array BioPharma, Kyowa Kirin Pharmaceutical Development, Mersana Therapeutics, Unum Therapeutics, BeiGene, Calithera Biosciences, Innovent Biologics, Seagen, Springworks Therapeutics, Bayer HealthCare, AstraZeneca Australia, Servier, PharmaMar, Genentech, EMD Serono, University of Texas MD Anderson Cancer Center, Chugai Pharmaceutical, Amgen Australia, Eli Lilly Australia, Daiichi Sankyo Europe
OpenAlex ID: W4408994826
FWCI:
Cites:
Cited by:
Related to: 10